Compare Grab Holdings Ltd. (GRAB) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs Incyte Corporation — how do they compare? Grab Holdings Ltd. trades at $3.62 (market cap $15.26B), while Incyte Corporation trades at $121.44 (market cap $24.54B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| GRAB | INCY | |
|---|---|---|
Market Cap | $15.26B | $24.54B |
Sector | Technology | Health |
52-Week High | $6.45 | $129.93 |
52-Week Low | $3.27 | $81.61 |
Enterprise Value | $10.99B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GRAB trades at $3.625, down 1.23% on the day, showing strong fundamental momentum with three consecutive quarterly earnings beats and a significant turnaround to profitability. The company reported Q2 2026 EPS of $0.06 versus $0.05 expected, with revenue growth accelerating to $3.37 billion in 2025. Technical indicators show a bullish trend with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions near-term.
GRAB presents a compelling growth story with improving profitability and strong analyst support (91.67% buy ratings). The company's raised 2026 guidance and expanding super app ecosystem signal continued momentum. Key risks include volatile cash flow patterns, competitive pressures in Southeast Asia, and recent insider selling activity that warrants monitoring.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
